Characterization of the VHH-Fc construct rimteravimab in healthy adults and patients hospitalized for mild-to-moderate COVID-19: Two Phase 1 randomized clinical trials
PLOS Medicine · 29.05.2026 · 23 (5) · e1004609
DOI: 10.1371/journal.pmed.1004609 ↗Kurz gefasst
Klinische Studie (Phase I) in der Zeitschrift PLOS Medicine, online erschienen am 29.05.2026. Verfasst von Ellen Jansen und 9 weiteren Autor:innen. Beteiligte Einrichtung: ExeVir Bio BV, Ghent, Belgium. Hauptthemen laut MEDLINE: COVID-19 Drug Treatment, Antibodies, Monoclonal, Humanized, SARS-CoV-2, Immunoglobulin Fc Fragments. Die Arbeit nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Agentschap Innoveren en Ondernemen, Service Public de Wallonie-Recherche, Horizon 2020 Framework Programme.
Abstract (Originalsprache)
Background
Variable Heavy domain of Heavy chains (VHH) are innovative tools to target unique epitopes, yet few have been developed as heavy chain-only antibodies for clinical use. Rimteravimab (referred to here as XVR011) is a humanized antibody developed for the treatment of mild-to-moderate coronavirus disease 2019 (COVID-19), consisting of two identical VHHs targeting the receptor binding domain (RBD) of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike, with a human immunoglobulin (Ig) G1 fragment constant of antibody (Fc), silenced for Fc effector functions. We conducted two Phase 1 studies in healthy volunteers or hospitalized COVID-19 patients to evaluate its safety, tolerability, pharmacokinetics and immunogenicity. Methods and findings A randomized, double-blinded, single-center, placebo-controlled, single ascending dose study was performed in healthy volunteers (Phase 1a, EXEVIR0102, EudraCT 2021-003707-17), in parallel to an open-label, multi-center, single ascending dose study in patients hospitalized for mild to moderate COVID-19 (Phase 1b, EXEVIR0101, EudraCT 2020-005299-36, NCT04884295). Participants received a single intravenous infusion of 250, 500 or 1,000 mg of XVR011. The primary objective for both trials was the safety and tolerability of XVR011. Pharmacokinetics were evaluated as a secondary objective in Phase 1a and as an exploratory objective in Phase 1b. Efficacy (evaluated as respiratory parameters and COVID-19 clinical status) and antiviral activity in patients were evaluated as a secondary objective in Phase 1b. Immunogenicity was evaluated as an exploratory objective. Part 2 of the EXEVIR0101 study (initially a phase 1b/2 study) was not conducted due to the loss of XVR011 potency against SARS-CoV-2 Omicron BA.2. Demographics, safety, efficacy, and immunogenicity were analyzed using descriptive statistics, while pharmacokinetics were analyzed with noncompartmental pharmacokinetics (PK) modeling. In the Phase 1a study, there were no infusion-related reactions, serious treatment-emergent adverse events (TEAEs) or TEAEs grade ≥3. 22/30 volunteers (73.3%) reported 53 TEAEs (49 Grade 1, 4 Grade 2) with none being related to XVR011. The most common TEAE was headache ( n = 8, 26.7%) in various treatment groups. In the Phase 1b study, 27 hospitalized patients were enrolled, and followed up to 30 days. Seven patients (25.9%) reported a total of 15 TEAEs, the majority (80%) being mild to moderate (Grade 1–2). There were no treatment-related serious TEAEs. All TEAEs resolved by the end of the study. Peak exposure (maximal concentration, C max ) and systemic exposure (area under the curve, AUC 0-t , and AUC 0-inf ) for XVR011 increased dose-proportionally. Geomean half-life ranged from 15.4 to 17.0 days in Phase 1a, while individual half-life ranged from 11.4 to 15.6 days in Phase 1b. SARS-CoV-2 viral load, as detected in nasopharyngeal samples by reverse transcription and quantitative polymerase chain reaction (RT-qPCR), decreased similarly in all cohorts compared to baseline. No treatment-induced anti-drug antibodies (ADA) were detected in Phase 1a. In Phase 1b, higher XVR011 concentrations increased the likelihood of ADA formation, without impacting pharmacokinetics and pharmacodynamics. No obvious dose-response in COVID-19 clinical status or respiratory parameters was observed. Technological limitations included study size, absence of placebo for the Phase 1b, absence of repeated dosing, evolving SARS-CoV-2 variants and standard-of-care.
Conclusions
XVR011 displayed a favourable safety, tolerability, pharmacokinetics, and immunogenicity profile, both in healthy volunteers and in patients hospitalized for mild to moderate COVID-19. These data pave the way for the design and clinical development of VHH-Fc constructs.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- ExeVir Bio BV, Ghent, Belgium.
- POG Pharmacometrics Ltd, London, United Kingdom.
- Early Development Services, PRA Group BV, a PRA Health Sciences Company, Groningen, The Netherlands.
- Clinical Republican Hospital "Timofei Mosneaga", ARENSIA Exploratory Medicine, Chisinau, Republic of Moldova.
- Infectious Diseases and Internal Medicine, Centre hospitalier Universitaire de Liège (CHU), Liège, Belgium.
ORCID-Profile: Ellen Jansen, Florence Herschke, Per Olsson Gisleskog, Angélique Boerboom, Michel Moutschen, Dominique Tersago
Förderung
- Agentschap Innoveren en Ondernemen
- Service Public de Wallonie-Recherche
- Horizon 2020 Framework Programme
- ExeVir Bio BV
Zitieren
APA
Jansen, E., Bockstal, V., Herschke, F., Olsson Gisleskog, P., Rinaldi, M., Boerboom, A., Hadi, S., Gaibu, N., Moutschen, M., & Tersago, D. (2026). Characterization of the VHH-Fc construct rimteravimab in healthy adults and patients hospitalized for mild-to-moderate COVID-19: Two Phase 1 randomized clinical trials. PLOS Medicine, 23(5), e1004609. https://doi.org/10.1371/journal.pmed.1004609
Vancouver
Jansen E, Bockstal V, Herschke F, Olsson Gisleskog P, Rinaldi M, Boerboom A, et al. Characterization of the VHH-Fc construct rimteravimab in healthy adults and patients hospitalized for mild-to-moderate COVID-19: Two Phase 1 randomized clinical trials. PLOS Medicine. 2026;23(5):e1004609. doi:10.1371/journal.pmed.1004609
BibTeX
@article{Jansen2026,
author = {Jansen, Ellen and Bockstal, Viki and Herschke, Florence and Olsson Gisleskog, Per and Rinaldi, Manuela and Boerboom, Angélique and Hadi, Salah and Gaibu, Natalia and Moutschen, Michel and Tersago, Dominique},
title = {Characterization of the VHH-Fc construct rimteravimab in healthy adults and patients hospitalized for mild-to-moderate COVID-19: Two Phase 1 randomized clinical trials},
journal = {PLOS Medicine},
year = {2026},
volume = {23},
number = {5},
pages = {e1004609},
doi = {10.1371/journal.pmed.1004609}
}
EUVIMED